UBS raised the firm’s price target on Cryoport (CYRX) to $11 from $10 and keeps a Buy rating on the shares. The divestiture of CryoPDP is strategically positive, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYRX:
- Strategic Sale and Partnership Propel CryoPort’s Focus on Cell and Gene Therapy
- CryoPort’s Strategic Shift: Hold Rating Amidst Partnership with DHL and Market Expansion
- CryoPort’s Strategic Sale to DHL: Enhancing Growth and Strengthening Financial Position
- DHL Group acquires Cryopdp from Cryoport, terms not disclosed
- CryoPort Sells CRYOPDP to DHL for $138 Million